Mycoses in patients with haematological malignancies and stem cell transplantation;Gombafertozések az onkohematológiában és hemopoetikus ossejtátültetés kapcsán

Lege Artis Medicinae

Volumn 15, Issue 10, 2005, Pages 713-720

  Prinz, Gyula ^a,b   Sinkó, János ^a,b   Nikolova, Radka ^b,c  

^a IV Sz Belgyógyászati Osztály ^*  (Hungary)

^b Szent Laszlo Hospital   (Hungary)

^c Országos Hematológiai és Infektológiai Intézet   (Hungary)

Author keywords

Caspofungin; Hematological malignancy; Invasive mycoses; Stem cell transplantation; Voriconazole

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CASPOFUNGIN; CLOTRIMAZOLE; COTRIMOXAZOLE; DEOXYCHOLIC ACID; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; NYSTATIN; SULFAMETHOXAZOLE; TRIMETHOPRIM; VORICONAZOLE;

ASPERGILLOSIS; ASPERGILLUS; CANDIDA; CANDIDIASIS; CHRONIC DISEASE; CRYPTOCOCCOSIS; DIAGNOSTIC PROCEDURE; DRUG RESISTANCE; ESOPHAGITIS; HEMATOLOGIC MALIGNANCY; HUMAN; MUCORMYCOSIS; MYCOSIS; NEUTROPENIA; OROPHARYNX CANDIDIASIS; PATIENT; PNEUMOCYSTIS; PROPHYLAXIS; REVIEW; STEM CELL TRANSPLANTATION;

EID: 27344431920     PISSN: 08664811     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004;38:161-89.
2. Sullivan KM, Dykewicz, Longworth DL, et al. Preventing opportunistic infections after hematopoetic stem cell transplantation: The Centers for Disease Control and Prevention, Infectious Diseases Society of America, and American Society for Blood and Marrow Transplantation Practice Guidelines and beyond. Hematology. Am Soc Hematol Educ Program 2001; p. 392-421.
3. Denning DW, Kibler CC, Barnes RA. British Society for Medical Micology proposed standards of care for parients with invasive fungal infections. Lancet Infect Dis 2003;3:230-40.
4. Böhme A, Ruhnke M, Buchheidt D, et al. Treatment of fungal infections in hematology and oncology. Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2003;82 (Suppl2):133-40.
5. Aguado JM, Garcia Rodrigez JA, Gobernado M, et al. Prophylaxis and treatment of fungal infections in oncohematological patients. Rev Esp Quimioterap 2002;15:387-401.
6. Bouza E, Peláez T, Pérez-Molina J, et al. Demolition of a hospital building by controlled explosion: the impact on filamentous fungal load in internal and external air. J Hosp Infection 2002; 52:234-42.
7. Anaissie EJ, Penzak SR, Dignani CM. The hospital water supply as a source of nosocomial infections. Arch Intern Med 2002;162: 1483-92.
8. Sinkó J, Prinz Gy, Nikolova R. Hematológiai betegek gombainfekciói; diagnózis, kezelés és megelozés. Hemat Transzf 2004;37: 231-47.
9. de Pauw B. Preventive use of antifungal drugs on patients treated for cancer. JAC 2004;53:130-32.
10. Pizzo PA, Robichaud KJ, Gill FA, et al. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982;72:101-11.
11. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999;340:764-71.
12. White MH, Bowden RA, Sandier ES, et al. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis 1998;27:296-302.
13. Wingard JR, White MH, Anaissie E, et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis 2000;31:1155-63.
14. Walsh TJ, Pappas P, Winston DJ, Lazarus HM, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002;346:225-34.
15. Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antufungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004;351:1391-402.
16. Malik IA, Moid I, Aziz Z, et al. A randomized comparison of fluconazole with amphotericin B as empiric anti-fungal agents in cancer patients with prolonged fever and neutropenia. Am J Med 1998;105:478-83.
17. Pfaller MA, Jones RN, Messer SA, et al. National surveillance of nosocomial blood stream infections due to species of Candida other than Candida albicans frequency of occurence and antifungal susceptibility in the SCOPE program. SCOPE Participant Group. Diagn Microbiol Infect Dis 1998;30:121-9.
18. Abi-Said D, Anaissie E, Uzun O, et al. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 1997;24:1122-8.
19. Nguyen MH, Peacock JE jr., Morris AJ, et al. The changing face of candidaemia: emergence of non Candida albicans species and antifungal resistance. Am J Med 1996;100:617-23.
20. Singh N. Changing spectrum of invasive candidiasis and its therapeutic implications. Clin Microbiol Infect 2001;7 (Suppl2):1-7.
21. Sinkó J, Csomor J, Nikolova R. Invazív gombainfekció k elofordulása onkohaematologiai betegekben. Orv Hetil 1998;139:409-12.
22. Rex JH, Pfaller MA. Has antifungal susceptibility testing come of age? Clin Infect Dis 2002;35:982-9.
23. Villaneuva A, Arathoon E, Gottuso E, et al. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis 2001;33:1529-35.
24. Arathoon E, Gottuso E, Noriega L, et al. Randomised double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharingeal and oesophageal candidiasis. Antimicrob Agents Chemother 2002;46:451-7.
25. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002;347:2020-9.
26. Anaissie EJ, Darouiche RO, Abi-Said D, et al. Management of invasive candidal infections: results of a prospective, randomised multicenter study of fluconazole versus amphotericin B and review of literature. Clin Infect Dis 1996;23:964-71.
27. Rex JH, Pappas PG, Karchmer AW. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazol plus amphotericin B as therapy for candidaemia and its consequences in non-neutropenic subjects. The National Institute of Allergy and Infectious Diseases Study Group. Clin Infect Dis 2001;36:1221-8.
28. Walsh T, Rex JH. All catheter-related candidemia is not the same: assessment of the balance between the risk and benefits of removal of vascular catheters. Clin Infect Dis 2002;34:600-2.
29. Slavin MA, Szer J, Grigg AP, et al. Guidelines for the use of antifungal agents in the treatment of invasive Candida and mould infections. Intern Med J 2004;34:192-200.
30. Goodman JL, Wintson DJ, Greenfield RA, et al. A controlled trial of fluconazol to prevent fungal infections in patients undergoing bone marrow transplantaion. N Engl J Med 1992;326:845-51.
31. Marr K, Seidel K, Slavin M, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: Long term follow-up of a randomized, placebo-controlled trial. Blood 2000;96:2055-61.
32. Yamazaki T, Kume H, Murase S, et al. Epidemiology of visceral mycoses: analysis of data in Annual of patholoycak Autopsy Cases in Japan. J Clin Microbiol 1999;37:1732-8.
33. McNeil MM, Nash SL, Hajjeh RA, et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis 2001;33:641-7.
34. Lin S-J, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001;32:358-66.
35. Denning DW, Marinus A, Cohen J, et al. An EORTC prospective survey of invasive aspergillosis in hematological patients: diagnosis and therapeutic outcome. J Infect 1998;37:173-80.
36. Nikolova R. Invazív mycosisok diagnosztikája és elofordulása hematológiai és csontvelotranszplantált betegekben. A Magyar Infektológiai Társaság 31. Konresszusa. Gyula: 2003. október 9-11.
37. Ascioglu S, Rex JH, de Pauw BE, et al. Defining opportunistic fungal infections in immunocompromised patients with cancer and hemopoietic stem cell transplantation international consensus. Clin Infect Dis 2002;34:7-14.
38. Caillot D, Casasnovas O, Bernard A, et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 1997;15:139-47.
39. Caillot D, Couaillier JF, Bernard A, et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 2001;19:253-9.
40. Hauggaard A, Ellis M, Ekelund L. Early chest radiography and CT in the diagnosis, management and outcome of invasive pulmonary aspergillosis. Acta Radiol 2002;43:292-8.
41. Reichenberger F, Habicht JM, Gratwohl A, et al. Diagnosis and treatment of invasive pulmonary aspergillosis in neutropenic patients. Eur Respir J 2002;19:743-75.
42. Maschmeyer G, Beinert T, Buchheidt D, et al. Diagnosis and antimicrobial therapy of pulmonary infiltrates in febrile neutropenic patients. Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2003;82(Suppl2):118-26.
43. Mennink-Kersten MA, Donnelly JP, Verweij PE. Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis 2004;4:349-57.
44. Kawazu M, Kanada Y, Nannya Y, et al. Prospective comparison of the diagnostic potential of real-time PCR, double-sandwich enzyme-linked immunoabsorbent assay for galactomannan, and a (1 → 3)-beta-D-glucan test in weekly screening for invasive aspergillosis in patients with hematological disorders. J Clin Microbiol 2004;42:2733-41.
45. Wiederhold NP, Lewis RE, Kontoyannis DP. Invasive aspergillois in patients with hematologic malignancies. Pharmacotherapy 2003;23:1592-610.
46. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-15.
47. Maertens J, Raad J, Sable CA, et al. Multicenter, noncomparative study to evaluate safety and efficacy of caspofungin in adults with invasive aspergillosis refractory or intolerant to amphotericin B, AMB lipid formulations or azoles. Toronto, Ontario, Canada: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000. abstr. No 1103.
48. Maertens J, Raad I, Petrikkos G, et al. Update of the multicenter, noncomparative study of caspofungin (CAS) in adults with invasive aspergillosis (IA) refractory (R) or intolerant (I) to other antifungal agents: analysis of 90. San Diego: 41th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002. abstr. No 3269.
49. Siemens DA, Kahn VI, Judson MA, et al. Practice guidelines for diseases caused by Aspergillus. Clin Infect Dis 2000;30:696-709.
50. Marr K, Boeckh M, Carter RA, et al. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004;39:797-802.
51. Ozer H, Armitage JO, Bennett CL, et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence based, clinical practice guidelines. J Clin Oncol 2000;18:3558-85.
52. Hübel K, Dale DC, Engert A, et al. Current status of granulocyte (neutrophil) transfusion therapy for infectious diseases. J Infect Dis 2001;183:312-8.
53. Habicht JM, Reichenberger F, Gratwohl A, et al. Surgical aspects of resection for suspected invasive pulmonary fungal infection in neutropenic patients. Ann Thorac Surg 1999;68:321-5.
54. Hajjeh RA, Warnock DW. Contrepoint: invasive aspergillosis and the environment - rethinking our approach to prevention. Clin Infect Dis 2001;33:1549-52.
55. Cornely OA, Böhme A, Buchheidt D, et al. Prophylaxis of invasive fungal infections in patients with hematological malignancies and solid tumours. Ann Hematol 2003;82(Suppl2):186-200.
56. Bow EJ, Lavendiere M, Lussier N, et al. Antifungal prophylaxis for severely neutropenic chemotherapy patients. A meta-analysis of randomized-controlled trials. Cancer 2002;94:3230-46.
57. Marr KA, Crippa F, Leisenring W, et al. Itraconazole versus fluconazole for prevention of fungal infection in patients receiving allogeneic stem cell transplants. Blood 2004;103:1527-33.
58. Winston DJ, Maziarz RT, Chandrasekar PH, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic stem-cell transplant recipients. Ann Intern Med 2003;138:705-13.
59. Cordonnier C, Maury S, Pautas C, et al. Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients. Bone Marrow Transplant 2004;33:943-8.
60. Saag MS, Graybill RJ, Larsen RA, et al. Practice guidelines for the management of cryptococcal disease. Clin Infect Dis 2000;30: 710-8.
61. Herbrecht R, Letscher-Bru V, Bowden RA, et al. Treatment of 21 cases of invasive mucormycosis with amphotericin B colloid dispersion. Eur J Clin Microb Infect Dis 2001;20:460-6.
62. Thomas CF, Limper AH. Pneumocystis pneumonia. N Engl J Med 2004;350:2487-98.